Back

Updated on 25/08/2026

DOLFLAM 50 mg Film-coated tablets

Diclofenac Potassium

Film-coated tablets

Long-term treatment of chronic inflammatory rheumatic conditions and severe osteoarthritis; short-term treatment of joint inflammation; relief of painful menstrual cramps

Fabriqué en France

  • Packaging:

    50 film-coated tablets

  • CONTRAINDICATIONS

    If your doctor has told you that you have an intolerance to certain sugars, contact him or her before taking this medication. This medication is not recommended for patients with galactose
    intolerance,
    Lapp lactase deficiency, or glucose-galactose malabsorption syndrome (rare hereditary disorders).

    This medication contains an azo dye (E110) and may cause allergic reactions. This medication contains small amounts of ethanol (alcohol), less than 100 mg per film-coated tablet,

    which evaporate during the manufacturing process.

    Never take DOLFLAM in the following cases:

    • After the fifth month of pregnancy (24 weeks of amenorrhea);

    • A history of allergy or asthma triggered by taking this medication or a related medication, particularly other nonsteroidal anti-inflammatory drugs (NSAIDs) or acetylsalicylic acid (aspirin);

    • A history of allergy (hypersensitivity) to the active ingredient or to any of the other ingredients in DOLFLAM;

    • A history of gastrointestinal bleeding or ulcers related to previous treatment with NSAIDs;

    • Active or recurrent
    stomach or duodenal ulcer;
    • Current gastrointestinal bleeding, cerebral hemorrhage, or other bleeding;

    • Severe liver, kidney, or heart disease;

    • Children weighing less than 35 kg (due to the inappropriate dosage of this medication).

Report

Do you wish to make a report?

In accordance with legal and regulatory obligations governing health and safety, you can report any adverse event (medicinal or cosmetic) or suspected quality defect related to the use of one of our products.

This information is crucial for the ongoing evaluation of our safety profile. Please submit your report: directly to our monitoring department via the contact form for medications; and/or via our telephone number +33 (0)3 86 20 21 64.